logo-loader
viewIXICO PLC

Trading Update for year ended 30 September 2019

/**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:14.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h2{margin-top:10.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:13.0pt;font-family:"Calibri","sans-serif";color:#31849B;font-weight:bold;}h3{margin-top:12.0pt;margin-right:0cm;margin-bottom:3.0pt;margin-left:0cm;line-height:115%;font-size:13.0pt;font-family:"Calibri Light","sans-serif";font-weight:bold;}h4{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:11.0pt;font-family:"Cambria","serif";color:#365F91;font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .ak{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ak{}p.bo{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}span.bm{color:black}p.ae,li.ae,div.ae{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}span.bp{font-family:"Arial","sans-serif";font-size:11.0pt;font-family:"Calibri","sans-serif"}span.bj{font-size:11.0pt;color:black}p.bq{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.br{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: center}p.bs{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;font-size:10.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt; text-align:justify} span.bg{font-size:11.0pt}p.bt{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}p.bu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}span.bv{color: black; font-div: italic}p.bw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; margin-left: 0cm; margin-right: -12.5pt; margin-top: 0cm; text-align: justify}table.bx{margin-left:-5.4pt;border-collapse:collapse}td.az{width:286.65pt;padding:0cm 5.4pt 0cm 5.4pt}p.by{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 12.1pt; text-align: justify}td.ax{width:142.55pt;padding:0cm 5.4pt 0cm 5.4pt}p.bz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;text-align:justify} p.ca{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify}p.cb{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}span.cc{color: black; font-weight: bold}p.cd{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align:justify}span.ce{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cf{margin-top:0cm;margin-right:0cm;margin-bottom:13.5pt;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-bottom: 0cm; text-align: justify}span.aq{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.ao{line-height:115%}span.cg{color:black}span.ch{font-size:10.0pt; color:black} span.ci{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bk{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.cj{color:blue;text-decoration:underline;font-family: "Calibri","sans-serif"; font-size: 11.0pt; text-decoration: none} /**/
RNS Number : 8358P
IXICO plc
15 October 2019
 

15 October 2019

IXICO plc

("IXICO" or the "Company")

 

Trading Update for year ended 30 September 2019

 

Company reports fast tracked achievement of initial year positive EBITDA,

40% revenue growth and strong cash position

 

 

IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, is pleased to announce a trading update for the year ended 30 September 2019.  IXICO is expecting its first full year of positive earnings before interest, tax, depreciation and amortisation ("EBITDA") since listing.  This better than forecast performance has been driven by accelerated revenue growth and builds on the breakeven performance reported in the Company's interim statement.

 

For the year ended 30 September 2019, revenue increased year-on-year by 40% to £7.6 million (2018: £5.4 million).  The Company will continue to benefit from a healthy contracted order book of £15.9 million, which takes account of the client early trial cessation reported on 9 August 2019, and retains a strong position for growth delivery in 2020 and beyond.

 

Net cash at 30 September 2019 was £7.3 million (2018: £7.9 million).  The strong cash position enables the Company to continue to organically fund investment to strengthen its technology and innovation portfolio and to grow the Company market position in the global biopharmaceutical clinical trials market for AI-driven analytics.

 

The Company intends to announce its audited results for the year ended 30 September 2019 in early December 2019.

 

 

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

"We are very pleased to have again delivered on our client and financial commitments, exceeding full year guidance, while continuing to invest in the long-term future of the Company. 2019 has been a pivotal year in the Company's transformation into a profitable, scalable business, and we enter 2020 on a strong growth trajectory supported by our order book, highly talented staff and strengthened leadership team."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer




Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)




Optimum Strategic Communications

 +44 (0) 203 950 9144

Mary Clark / Supriya Mathur / Manel Mateus


[email protected]


 

About IXICO

 

IXICO's mission is to advance medicine and human health in neuroscience by turning data into clinically meaningful information, providing valuable new insights.  We achieve this by developing, validating and deploying novel Artificial Intelligence (AI) technology in clinical trials to improve the success and efficiency of the development pathway.

 

Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma ROI and R&D productivity through the adoption of breakthrough data analytics in precision medicine.  Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare diseases today, providing detailed insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.

 

More information is available on www.IXICO.com

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
TSTZMMMGVDGGLZM

Quick facts: IXICO PLC

Price: 70.5

Market: AIM
Market Cap: £33.07 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Proactive meets IXICO's new chief business officer Lammert...

Lammert Albers sits down with Proactive London's Andrew Scott soon after his appointment as IXICO PLC’s (LON:IXI) chief business officer. With expertise of the Alzheimer's disease trials market he says he'll be responsible for executing the company's global business development strategy in...

1 week, 2 days ago